قالب وردپرس درنا توس
Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ 7 Fat and reasonable predictions for marijuana shares in 2019 – The Motley Fool

7 Fat and reasonable predictions for marijuana shares in 2019 – The Motley Fool



Move aside, Nostradamus. There is a new prognosticator in town. For me.

Instead of composing cryptic quatrains about strange global events far in the future, I limit my predictions to a particular area – marijuana shares. And I want to make them crystal clear so they are easy to interpret. Finally, instead of looking into the distant future, I will focus exclusively on next year.

So without further ado, here are my seven fat-rich predictions for marijuana stocks in 2019.

  The man keeps short with 2019 written on it behind a glass ball.

Image Source: Getty Images.

first USA legalizes marijuana – marijuana shares soar, Jeff Sessions cries

I predict that Sen. Cory Gardner (R-CO) and Sen. Elizabeth Warren (D-MA) finally will succeed in "strengthening the tenth change through the appealing states (STATES) Act" passed in the US Senate. A similar bill will pass the House of Representatives, with President Trump, who quickly signs the law into law.

Marijuana shares so high that some incumbents are considering including the word "cannabis" in their names. Oh, and former US Attorney General Jeff Sessions crying when interviewed on television about marijuana legalization news, spurring the biggest social media meme of the year.

2nd At least three $ 1 billion plus is about a CEO who eats his words

Canopy Growth (NYSE: CGC) had his $ 4 billion mention with Constellation Brands in 2018. Cronos Group (NASDAQ: CRON) had its $ 1.8 billion investment from Altria . Next year, I expect at least three other deals of more than $ 1 billion between marijuana growers and companies operating outside the cannabis industry.

Tilray (NASDAQ: TLRY) may or may not be involved in any of these major offers. In any case, Tilray CEO Brendan Kennedy will literally eat his words by gobble down a transcript of his 2018 interview with CNBC hosted by Jim Cramer, saying he did not want to be a partner with Anheuser-Busch InBev – It would build another Anheuser-Busch InBev.

Oh, wait … Tilray has just announced a collaboration with (drum roll thanks) Anheuser-Busch. Perhaps Kennedy would instead eat his latest words that Tilray was not interested in an investment from his new joint venture partner.

3rd Cannabis-infused beverages market explodes, more popular with millennia than soft drinks

My prognosis is that Canada completes its rules for cannabis edibles in 2019, with Canopy Growth and Constellation instantly launching more than a dozen new cannabis-infused beverages. Other companies quickly follow suit. Millennials in Canada spend more on cannabis infused drinks in the fourth quarter of next year than they do on soft drinks.

At the same time, the American hemp-based CBD-infused beverage market also plays a major role. Canopy Growth scrambles to enter the fast-growing market before the end of the year in advance of its highly anticipated Super Bowl advertising with Rolling Stones, singing a version of one of their biggest hits with revised lyrics, "I can get one some satisfaction. "

4th First American plant-based cannabinoid drug is a big hit, Big Pharma-execs harms after panicking

Despite some nudity negativism by skeptics GW Pharmaceuticals (NASDAQ : GWPH) Epidiolex, the first plant-based cannabinoid drug approved in the United States, becomes a crushing commercial success. Even pessimistic analysts estimate that Epidiolex is likely to be a blockbuster within a few years.

As Epidiolex sales are steadily increasing, several famous Big Pharma executives are forced to receive medical attention for injuries received from turning on their foreheads. These slush originate from the leaders who read the stories of their companies that market cannabis-based drugs in the early 20th century.

5th At least one Canadian marijuana stock has no dilution, giving rise to street celebrations in major Canadian cities

After many large Canadian marijuana stocks watered down to smiths in 2018, the New Year gives a very different scenario. At least one Canadian marijuana producer actually goes all year in 2019 without issuing a single new share.

Zero dilution at first stun investors. But when the shock slides, they storm the streets of the big Canadian cities to party.

6th Mexico Considering Building a Wall to Prevent an Invasion of Canadian Marijuana Breeders

Mexico's Supreme Court overturned the country's ban on recreational marijuana in 2018. I predict that the country's lawmakers will fully legalize the sale and use of recreational weeds in 2019. [19659002] Although the country will first embrace the idea of ​​Canadian marijuana producers flocking to shop in Mexico, some politicians will not be happy. A bill has been introduced to build a wall along the Mexico United States. border to prevent more Canadian marijuana growers from going south. However, the bill dies in committee after receiving official approval from US President Donald Trump.

7th Listed short-term issues update that it looked like marijuana stocks all the time, was just fun in previous negative attacks

Citron Research and its founder Andrew Left caused shares in the Cronos Group to fall in August 2018 with a report titled Cronos : The dark side of the cannabis room. Incidentally, the Cronos Group became one of the best possible marijuana stocks in 2018.

In 2019, my forecast is that Citron makes a complete face. It publishes a new online report that says all that was said before about marijuana stocks was really made in jest. Citron's report also says that estimates of a global marijuana market of $ 150 billion are off, with the actual figure closer to $ 148 billion.

All fun aside

Of course, my predictions for marijuana stores in 2019 were made with heavily implanted in cheek. However, there are some aspects of the predictions that I suppose will actually happen next year.

My belief is that there is a relatively good chance that the state's bill will pass, for example. Although this law does not legally legalize marijuana in the United States, it would mean that the federal government would not interfere with states that have legalized marijuana for either medical or recreational purposes.

I think there will be more big deals between companies operating outside the cannabis industry and the marijuana producers. The cannabis-infused beverage market is likely to get off to a good start in 2019. Epidiolex may just surprise some observers with its early sales momentum.

With its $ 4 billion cash investment and revenue, Canopy Growth cannot further dilute its stock next year. Mexico could legitimately legalize recreational cannabis and attract significant interest from the large Canadian marijuana producers. And while the prediction of lemon research will not be met, the growth of the global cannabis industry may cause the vendor to take stock of other industries.

Here is a more serious prediction as a bonus. Four marijuana stocks were mentioned in my capricious predictions – Canopy Growth, Cronos Group, GW Pharmaceuticals and Tilray. I predict that the biggest marijuana stock wins in 2019 will more than quadruple and will be … none of the above.


Source link